Literature DB >> 29653826

The surgery and repeat aspiration outcomes of the atypia of undetermined significance/follicular lesion of undetermined significance category in The Bethesda System for Reporting Thyroid Cytopathology.

I-Shiow Jan1, Ya-Ting Lee2, Chun-Ming Wang2, Tsu-Yao Cheng1, Chih-Yuan Wang3, Tien-Chun Chang4, Shyang-Rong Shih5.   

Abstract

BACKGROUND/
OBJECTIVE: The atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category is one of six diagnostic categories of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). In this study, we report the diagnostic distribution of thyroid fine needle aspiration (FNA) cytology and analyze the outcome of AUS/FLUS cases.
METHODS: A total of 29,937 thyroid FNA results, reported between April 2012 and December 2016, were retrieved from the database of a medical center. We reviewed the electronic medical records and analyzed the management of these patients.
RESULTS: Overall frequency of AUS/FLUS is 3.1% in our laboratory, which is at the lower limit of the recommended range. Of these, 891 reports of AUS/FLUS from 770 patients were identified. Out of the 770 patients, 367 had surgical intervention. In these 367 patients, final surgical pathology yielded 204 (55.6%) malignancies, 12 indeterminateness (3.3%), and 151 (41.1%) benignity. Among these surgical patients, 113 (30.8%) had received a repeat FNA of the thyroid before thyroid resection. The difference between the malignancy rates among patients who directly received surgery after the first AUS/FLUS diagnosis (132 of 254, 52.0%) and patients having a repeat FNA before surgery (72 of 113, 63.7%) was not statistically significant.
CONCLUSION: Our results are in agreement with AUS/FLUS diagnoses in less than 7% of specimens, and confirm that it is appropriate to perform either a repeat thyroid FNA or thyroid lobectomy, with the clinical decision being subject to the standardized management protocols of the second edition of TBSRTC in the AUS/FLUS category.
Copyright © 2018. Published by Elsevier Taiwan LLC.

Entities:  

Keywords:  Atypia; The Bethesda System; Thyroid FNA cytology

Mesh:

Year:  2018        PMID: 29653826     DOI: 10.1016/j.asjsur.2018.02.008

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  3 in total

1.  Strategy to reduce unnecessary surgeries in thyroid nodules with cytology of Bethesda category III (AUS/FLUS): a retrospective analysis of 667 patients diagnosed by surgery.

Authors:  Yong Joon Suh; Yeon Ju Choi
Journal:  Endocrine       Date:  2020-04-15       Impact factor: 3.633

2.  Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.

Authors:  Mohamed Al Dawish; Asirvatham Alwin Robert; Khalid Al Shehri; Salwa Hawsawi; Muhammad Mujammami; Ibrahim Ali Al Basha; Mohannad Alrasheed; Shuaa Asiri; Muneerah Alzouman; Eyad Alkharashi
Journal:  Cureus       Date:  2020-05-19

3.  WHICH FACTORS ARE ASSOCIATED WITH MALIGNANCY IN THYROID NODULES CLASSIFIED AS BETHESDA CATEGORY 3 (AUS/FLUS) AND HOW DO THEY INFLUENCE THE PATIENT'S MANAGEMENT?

Authors:  C Kaya; E Bozkurt; D Türkyılmaz Mut; M Mihmanli; M Uludağ
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Oct-Dec       Impact factor: 0.877

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.